Table 3.
Predictors of overall survival among patients with ROS1-positive advanced NSCLC receiving crizotinib: an analysis of multivariable Cox proportional hazards regression model (n = 38, events = 16)
| Analysis variable | Adjusted HR (95% CI) | P value |
|---|---|---|
| Age group | ||
| < 65 years | Reference | |
| ≥ 65 years | 0.9 (0.2–3.4) | 0.8334 |
| Smoking history | ||
| Never smoked | Reference | |
| Current/former smoker | 6.0 (1.2–30.8) | 0.0326 |
| Not documented | 4.6 (0.6–33.0) | 0.1276 |
| ECOG performance score at index | ||
| 0 or 1 | Reference | |
| 2 | 4.9 (1.1–21.4) | 0.0337 |
| Not documented | 0.8 (0.2–3.8) | 0.8381 |
| BMI at index | ||
| Underweight/normal | Reference | |
| Overweight/obese | 0.3 (0.1–1.0) | 0.0562 |
| Unknown | 0.2 (0.03–2.0) | 0.1794 |
| Duration of time from initial NSCLC diagnosis to index date | 1.0 (0.9–1.0) | 0.6562 |
BMI body mass index, ECOG Eastern Cooperative Oncology Group